Description

2-Bromo-4-[6,6-Dimethyl-4-Oxo-3-(Trifluoromethyl)-4,5,6,7-Tetrahydro-1H-Indazol-1-Yl]Benzonitrile is a high-value, advanced pharmaceutical intermediate characterized by its complex heterocyclic structure incorporating bromo, cyano, and trifluoromethyl functional groups. This compound is critical for medicinal chemistry research and development, particularly in the synthesis of targeted small molecule therapeutics. It is primarily sought after by R&D departments and process chemists in the pharmaceutical, biotechnology, and fine chemical industries for constructing novel drug candidates.

Application

• Pharmaceutical Intermediate: Key building block in the synthesis of novel active pharmaceutical ingredients (APIs), especially in oncology and central nervous system (CNS) drug discovery programs.
• Medicinal Chemistry Research: Used as a core scaffold for structure-activity relationship (SAR) studies and lead optimization due to its versatile functional groups.
• Proteolysis Targeting Chimera (PROTAC) Development: Serves as a potential linker or warhead component in the design of targeted protein degradation molecules.
• Kinase Inhibitor Synthesis: The indazole core is a privileged structure in the development of selective kinase inhibitors for various disease targets.
• Agrochemical Research: Investigated as an intermediate for developing new generation herbicides and fungicides with enhanced activity.
• Material Science: Potential precursor for specialty polymers or liquid crystals, leveraging its aromatic and polar characteristics.

Basic Information

Product Name	2-Bromo-4-[6,6-Dimethyl-4-Oxo-3-(Trifluoromethyl)-4,5,6,7-Tetrahydro-1H-Indazol-1-Yl]Benzonitrile
CAS No.	908111-35-3
Molecular Formula	C₁₇H₁₅BrF₃N₃O
Molecular Weight	414.22 g/mol
Synonyms	2-Bromo-4-(6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)benzonitrile; 908111-35-3; 4-(2-Bromo-4-cyanophenyl)-6,6-dimethyl-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-one; 1-(2-Bromo-4-cyanophenyl)-6,6-dimethyl-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-4-one; Benzonitrile, 2-bromo-4-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl]-
EINECS	Contact for details

Quality Control

Our 2-Bromo-4-[6,6-Dimethyl-4-Oxo-3-(Trifluoromethyl)-4,5,6,7-Tetrahydro-1H-Indazol-1-Yl]Benzonitrile is manufactured under strict quality management systems to ensure batch-to-batch consistency and high purity suitable for research and development. Each lot is accompanied by a comprehensive Certificate of Analysis (COA) detailing purity, identity, and impurity profiles. We adhere to ICH guidelines for stability and impurity characterization, providing the traceability and documentation required for pre-clinical and early-phase clinical development.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry, well-ventilated area at a controlled room temperature (15-25°C). The compound may be hygroscopic (moisture-sensitive); keep the container tightly sealed under an inert atmosphere if necessary. Keep away from strong oxidizing agents.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (IR)	Conforms to structure
Identification (HPLC)	Retention time matches reference standard
Purity (HPLC)	≥ 97.0%
Water Content (KF)	≤ 0.5%
Residue on Ignition	≤ 0.1%
Single Unknown Impurity (HPLC)	≤ 1.0%
Total Impurities (HPLC)	≤ 3.0%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.